Enanta Pharmaceuticals Announces 96 Percent SVR12 in SAPPHIRE-I Study
First of Six All-Oral, Interferon-Free Phase 3 Hepatitis C Studies Using Regimen Containing ABT-450
Results from the 631 patient SAPPHIRE-I trial demonstrated a sustained virologic response at 12 weeks post-treatment (SVR12) of 96 percent in treatment-naïve adult patients chronically infected with GT1 HCV. The majority of patients were GT1a, considered the more difficult-to-treat subtype, and the SVR12 rates of GT1a and GT1b were 95 percent and 98 percent, respectively. These results were based on an intent-to-treat analysis and were achieved after 12 weeks of treatment. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen. The treatment regimen was well tolerated, with an equal percentage of patients in the active and placebo arms (0.6 percent) discontinuing treatment due to adverse events.
“Achieving high SVR rates in this trial is an important step toward our goal of providing a well-tolerated and highly effective all-oral treatment option that doesn’t currently exist for this important patient population,” stated
About Study M11-646 (SAPPHIRE-I)
SAPPHIRE-I is a global, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 12 weeks of treatment with ABT-333 (250mg), ribavirin (weight-based), both dosed twice daily, and the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ABT-267 (25mg) and dosed once daily in non-cirrhotic, GT1a and GT1b HCV-infected, treatment-naïve adult patients.
The study population consisted of 631 GT1 treatment-naïve patients with no evidence of liver cirrhosis. 473 patients were randomized to the 3D regimen plus ribavirin for 12 weeks, and 158 patients were randomized to placebo for the initial 12 weeks. Patients initially randomized to placebo for the first 12 weeks then received open-label treatment with the 3D regimen plus ribavirin for 12 weeks.
Following 12 weeks of treatment with AbbVie’s 3D regimen plus ribavirin, 96 percent (n=455/473) of patients achieved SVR12 based on intent-to-treat analysis where patients with missing values for any reason were considered treatment failures. In the active treatment arm, patients with GT1b infection achieved 98 percent SVR12 (148/151), while patients with GT1a achieved 95 percent SVR12 (307/322).
The most commonly reported adverse events in the 3D and placebo arms, respectively, were fatigue, headache and nausea. Discontinuations due to adverse events were reported in 0.6 percent of patients receiving the 3D regimen and 0.6 percent of patients receiving placebo. The rate of virologic relapse or breakthrough was low, occurring in 1.7 percent of patients receiving the 3D regimen.
Overview of AbbVie’s phase 3 clinical programs:
Study | Patients (N) | Treatment Regimen | Treatment Duration |
SAPPHIRE-I | GT1, treatment-naïve (631) |
• ABT-450/rb +ABT-267c • ABT-333 • Ribavirin |
12 weeks |
• Placebo | 12 weeks, then active treatment for 12 weeks | ||
SAPPHIRE-II | GT1, treatment-experienced (400a) |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
12 weeks |
• Placebo | 12 weeks, then active treatment for 12 weeks | ||
PEARL-II | GT1b, treatment-experienced (210 a) |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
12 weeks |
• ABT-450/r +ABT-267 • ABT-333 |
12 weeks | ||
PEARL-III | GT1b, treatment-naïve (400 a) |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
12 weeks |
• ABT-450/r +ABT-267 • ABT-333 • Placebo |
12 weeks | ||
PEARL-IV | GT1a, treatment-naïve (300 a) |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
12 weeks |
• ABT-450/r +ABT-267 • ABT-333 • Placebo |
12 weeks | ||
TURQUOISE-II | GT1, treatment-naïve and treatment-experienced (with compensated cirrhosis) (380 a) |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
12 weeks |
• ABT-450/r +ABT-267 • ABT-333 • Ribavirin |
24 weeks |
a projected study population
b ABT-450/ritonavir
c ABT-267 is co-formulated with ABT-450/r, administered as two pills once daily
ABT-450 is currently being studied in combination with other
Protease Inhibitor Collaboration with
In
About Hepatitis C Virus (HCV)
Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is typically spread through direct contact with the blood of an infected person. Hepatitis C increases a person’s risk of developing chronic liver disease, cirrhosis, liver cancer and death. There is an acute need for new HCV therapies that are safer and more effective for many variants of the virus.
About Enanta
Forward Looking Statements Disclaimer
This press release contains forward-looking statements, including with respect to clinical data, plans for announcing additional data, and the planned clinical development and regulatory submissions for ABT-450. Statements that are not historical facts are based on our management’s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors that may affect actual results include final results of ongoing clinical trials, the development and marketing efforts of
Source:
Investor:
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media:
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
- Print Page Print Page
- Email Alerts Email Alerts
- RSS Feeds RSS Feeds
- Contact IR Contact IR